Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Okay. We'll go ahead and get started.
Welcome, everyone, to the 2020 JP Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JP Morgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Sarepta, and presenting on behalf of the company is CEO, Doug Ingram. Doug?
Thank you. Thank you, Anupam. And to those in the room and also on the web, thank you for joining Sarepta this morning. Before I begin, let me say that I'll be making some forward-looking statements. Here is a laundry list of the various risks and uncertainties you may want to consider whenever one has the temerity to try to predict the future.
And with that, let's begin. So with the great advances that have occurred in genetic medicine, in 2018, Sarepta envisioned a revolution, and we built a strategy with the goal of being among the most
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |